ClinicalTrials.gg
CompletedNCT03311724Updated May 19, 2021Results posted

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

A Phase 2 interventional study of Tirzepatide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 13 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
32nd of 43
111 · median 160
Started
2017
with 2 others
Phase 2
5 of 43
none open now
Registered
3rd of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 2, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes (T2DM) for ≥6 months according to the Criteria for Diagnosing Type 2 Diabetes Mellitus (American Diabetes Association 2017).
  • Have of 7.0% to 10.5%, inclusive, as assessed by the central laboratory.
  • If on metformin, have been treated with stable doses of metformin for at least 3 months.
  • Have a (BMI) between 23 and 45 (Inclusive) kilograms per square meter.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes (T1D).
  • Have used any glucose-lowering medication other than metformin within 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past 12 months.
  • Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), Class III or Class IV heart failure, or cerebrovascular accident (stroke).
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or (ALT) level >2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial.
  • Have had chronic or acute pancreatitis any time prior to study entry.
  • Have an estimated (eGFR) \<45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation.
  • Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry.
  • Have any condition that is a for use of the GLP-1 RA class (per country-specific labels) at study entry or develop such condition between study entry and randomization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    4,8,12mg Tirzepatide

    Participants received Tirzepatide by subcutaneous (SC) injection in three dose escalations starting with 4 milligrams (mg) for four weeks followed by 8mg for four weeks followed by 12mg for four weeks.

    Drug: Tirzepatide

  • Experimental
    2.5,5,10,15mg Tirzepatide

    Participants received Tirzepatide by SC injection in four dose escalations starting with 2.5mg for two weeks followed by 5mg for two weeks followed by 10mg for four weeks followed by 15mg for four weeks.

    Drug: Tirzepatide

  • Experimental
    2.5,7.5,15mg Tirzepatide

    Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Placebo administered by SC injection.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Haemoglobin A1c (HbA1c)

    Least squares (LS) mean was calculated using mixed model repeated measures model (MMRM) with baseline + baseline BMI group + baseline metformin flag + treatment + time + treatment\*time as fixed factors.

    Time frame: Baseline, 3 Months

Secondary outcomes

  1. Percentage of Participants Achieving HbA1c Target of <7.0%

    Percentage of participants achieving HbA1c target of \< (less than) 7.0%.

    Time frame: 3 Months

  2. Change From Baseline in Fasting Blood Glucose (FBG)

    LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.

    Time frame: Baseline, 3 Months

  3. Change From Baseline in Body Weight

    LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.

    Time frame: Baseline, 3 Months

  4. Change From Baseline in Waist Circumference

    LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.

    Time frame: Baseline, 3 Months

  5. Number of Participants With Anti Drug Antibodies

    Number of participants with anti drug antibodies.

    Time frame: Baseline through 3 Months

  6. Number of Episodes of Total Hypoglycemia Episodes

    Number of episodes of total hypoglycemia episodes with plasma glucose \<= ( less than or equal to) 54 mg/dL.

    Time frame: Baseline through 3 Months

  7. Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide

    Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide.

    Time frame: Week 4, 8 12: Pre-dose

07

Results

Posted May 19, 2021

Participant flow

Participant flow — Overall Study
MilestonePlacebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Started26292828
Received at least one dose of study drug26292828
Completed treatment20272226
Completed23282627
Not completed3121
Withdrew: Physician decision0001
Withdrew: Protocol violation1010
Withdrew: Withdrawal by subject1100
Withdrew: Lost to follow-up1000
Withdrew: Sponsor decision0010

Outcome measures

PrimaryChange From Baseline in Haemoglobin A1c (HbA1c)

Least squares (LS) mean was calculated using mixed model repeated measures model (MMRM) with baseline + baseline BMI group + baseline metformin flag + treatment + time + treatment\*time as fixed factors.

Time frame:
Baseline, 3 Months
Reported as:
Least squares mean · Percentage of HbA1C
Change From Baseline in Haemoglobin A1c (HbA1c)
Percentage of HbA1CPlacebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Change From Baseline in Haemoglobin A1c (HbA1c)0.2 ± 0.21-1.7 ± 0.19-2.0 ± 0.20-1.8 ± 0.19
Statistical analysis
  • Placebo vs 4, 8 and 12mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.9 · 95% CI -2.5 to -1.4
  • Placebo vs 2.5, 5, 10, and 15mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -2.2 · 95% CI -2.8 to -1.7
  • Placebo vs 2.5, 7.5 and 15mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -2.0 · 95% CI -2.5 to -1.4
SecondaryPercentage of Participants Achieving HbA1c Target of <7.0%

Percentage of participants achieving HbA1c target of \< (less than) 7.0%.

Time frame:
3 Months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Target of <7.0%
percentage of participantsPlacebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Percentage of Participants Achieving HbA1c Target of <7.0%1074.18784.6
Statistical analysis
  • Placebo vs 4, 8 and 12mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 56.54 · 95% CI 9.43 to 338.97
  • Placebo vs 2.5, 5, 10, and 15mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 183.48 · 95% CI 22.0 to 999Maximum confidential interval is "\>999"
  • Placebo vs 2.5, 7.5 and 15mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 157.54 · 95% CI 21.63 to 999Maximum confidential interval is "\>999"
SecondaryChange From Baseline in Fasting Blood Glucose (FBG)

LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.

Time frame:
Baseline, 3 Months
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Blood Glucose (FBG)
milligrams per deciliter (mg/dL)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Change From Baseline in Fasting Blood Glucose (FBG)-12.3 ± 9.27-60.7 ± 8.21-70.2 ± 8.72-74.2 ± 8.67
Statistical analysis
  • Placebo vs 4, 8 and 12mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -48.5 · 95% CI -70.6 to -26.3
  • Placebo vs 2.5, 5, 10, and 15mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -58.0 · 95% CI -80.7 to -35.2
  • Placebo vs 2.5, 7.5 and 15mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -61.9 · 95% CI -84.6 to -39.2
SecondaryChange From Baseline in Body Weight

LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.

Time frame:
Baseline, 3 Months
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Change From Baseline in Body Weight-0.5 ± 0.86-5.3 ± 0.78-5.5 ± 0.80-5.7 ± 0.79
Statistical analysis
  • Placebo vs 4, 8 and 12mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -4.8 · 95% CI -7.1 to -2.6
  • Placebo vs 2.5, 5, 10, and 15mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -5.0 · 95% CI -7.2 to -2.7
  • Placebo vs 2.5, 7.5 and 15mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -5.2 · 95% CI -7.5 to -2.9
SecondaryChange From Baseline in Waist Circumference

LSMean was calculated using MMRM model with baseline + baseline HbA1C group + baseline BMI group + baseline Metformin flag + treatment + time + treatment\*time as fixed factors.

Time frame:
Baseline, 3 Months
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Waist Circumference
centimeter (cm)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Change From Baseline in Waist Circumference-2.5 ± 1.01-4.8 ± 0.90-4.9 ± 0.94-4.9 ± 0.93
Statistical analysis
  • Placebo vs 4, 8 and 12mg Tirzepatide · Mixed Models Analysis · p = 0.075 · Mean difference (final values): -2.2 · 95% CI -4.7 to 0.2
  • Placebo vs 2.5, 5, 10, and 15mg Tirzepatide · Mixed Models Analysis · p = 0.065 · Mean difference (final values): -2.4 · 95% CI -4.9 to 0.1
  • Placebo vs 2.5, 7.5 and 15mg Tirzepatide · Mixed Models Analysis · p = 0.065 · Mean difference (final values): -2.4 · 95% CI -4.9 to 0.2
SecondaryNumber of Participants With Anti Drug Antibodies

Number of participants with anti drug antibodies.

Time frame:
Baseline through 3 Months
Reported as:
Number · participants
Number of Participants With Anti Drug Antibodies
participantsPlacebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Number of Participants With Anti Drug Antibodies01084
SecondaryNumber of Episodes of Total Hypoglycemia Episodes

Number of episodes of total hypoglycemia episodes with plasma glucose \<= ( less than or equal to) 54 mg/dL.

Time frame:
Baseline through 3 Months
Reported as:
Number · Episodes
Number of Episodes of Total Hypoglycemia Episodes
EpisodesPlacebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Number of Episodes of Total Hypoglycemia Episodes0001
SecondaryPharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide

Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide.

Time frame:
Week 4, 8 12: Pre-dose
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide
nanograms per milliliter (ng/mL)4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide508 ± 366704 ± 518630 ± 414

Adverse events

Collected over Baseline through end of study (Up to 15 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/26 (0%)0/26 (0%)7/26 (26.9%)
4, 8 and 12mg Tirzepatide0/29 (0%)1/29 (3.4%)19/29 (65.5%)
2.5, 5, 10, and 15mg Tirzepatide0/28 (0%)0/28 (0%)18/28 (64.3%)
2.5, 7.5 and 15mg Tirzepatide0/28 (0%)0/28 (0%)22/28 (78.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
DiarrhoeaGastrointestinal disorders0/261/290/280/28
White blood cell count increasedInvestigations0/261/290/280/28
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg Tirzepatide
NauseaGastrointestinal disorders2/267/2911/2810/28
DiarrhoeaGastrointestinal disorders2/269/2910/289/28
Decreased appetiteMetabolism and nutrition disorders0/264/296/288/28
HeadacheNervous system disorders2/262/296/285/28
Abdominal painGastrointestinal disorders1/261/295/281/28
ConstipationGastrointestinal disorders0/261/293/285/28
VomitingGastrointestinal disorders1/265/295/285/28
DyspepsiaGastrointestinal disorders0/265/293/283/28
Abdominal distensionGastrointestinal disorders0/260/293/282/28
DizzinessNervous system disorders2/260/291/283/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
Mean56.0 ± 10.1361.2 ± 7.5655.5 ± 8.5456.6 ± 9.2157.4 ± 9.06
Sex: Female, Male
Sex: Female, Male(Participants)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
Female141412545
Male1215162366
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
Hispanic or Latino1615141459
Not Hispanic or Latino1014141452
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
American Indian or Alaska Native02103
Asian01214
Native Hawaiian or Other Pacific Islander00000
Black or African American175215
White2519202387
More than one race00022
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
United States26292828111
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1C)Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
Mean8.23 ± 1.228.35 ± 0.8978.48 ± 1.1718.35 ± 1.128.35 ± 1.094
Fasting Blood Glucose (FBG)
Fasting Blood Glucose (FBG)(millimoles per liter (mmol/L))Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
Mean9.68 ± 3.449.76 ± 3.0310.40 ± 4.0410.67 ± 4.2210.13 ± 3.69
Body Weight
Body Weight(kilogram (kg))Placebo4, 8 and 12mg Tirzepatide2.5, 5, 10, and 15mg Tirzepatide2.5, 7.5 and 15mg TirzepatideTotal
Mean89.58 ± 23.6987.98 ± 17.3588.74 ± 18.2189.59 ± 16.9188.95 ± 18.87

1 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Valley Research
    Fresno, California 93720, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Cotton O'Neil Diabetes and Endocrinology Center
    Topeka, Kansas 66606, United States
  • Clinical Research Professionals
    Saint Louis, Missouri 63141, United States
  • Aventiv Research
    Columbus, Ohio 43213, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37909, United States
  • Dallas Diabetes Endocrine Center
    Dallas, Texas 75230, United States
  • Consano Clinical Research
    Shavano Park, Texas 78231, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Apr 2018, 6 months.

Results were first posted in May 2021, 3 years after primary completion. A results delay was requested in Apr 2019.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 6 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2017
First posted
Oct 17, 2017
StartActual
Oct 19, 2017
Primary completionActual
Apr 24, 2018
CompletionActual
Apr 24, 2018
Results delay requested
Apr 24, 2019
Results first posted
May 19, 2021
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03311724
Responsible party
Sponsor
First posted
Oct 17, 2017
Start date
Oct 19, 2017
Primary completion
Apr 24, 2018
Completion
Apr 24, 2018
Results posted
May 19, 2021
Last update
May 19, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion